We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App




FDA Clears Compact Molecular COVID Test for Decentralized Care Settings

By LabMedica International staff writers
Posted on 17 Sep 2026

Decentralized healthcare settings such as urgent care clinics have historically struggled to deploy high-performance molecular testing. More...

Barriers include high upfront costs, fixed testing capacity, large instrument footprints, and workflow complexity. A newly FDA-cleared test now offers a hand-held platform that delivers higher analytical sensitivity and faster COVID results for both over-the-counter and professional use.

Aptitude Medical Systems’ (Goleta, CA, USA) next-generation Metrix COVID Test has received U.S. Food and Drug Administration (FDA) 510(k) clearance, the company’s first traditional clearance for the Metrix molecular diagnostics platform. Development was supported by the Biomedical Advanced Research and Development Authority (BARDA). Aptitude’s next-generation Metrix COVID/Flu Test is also under FDA review for 510(k) clearance, continuing the transition of its respiratory portfolio from emergency authorization to traditional clearance.

Metrix is a compact, hand-held molecular platform designed to make high-performance testing more accessible in decentralized care. It is cleared for both over-the-counter and professional use in CLIA-waived settings. The system is engineered for rapid results with simple workflows and a small footprint suited to urgent care and similar sites.

The updated Metrix COVID Test delivers approximately three-fold greater analytical sensitivity than the original Emergency Use Authorization (EUA) product and provides results about 30% faster. The platform is broadly available through major distributors in collaboration with Sekisui Diagnostics, and the company does not anticipate disruption during the upcoming respiratory season. Consistent with FDA transition policies, previously distributed EUA-authorized Metrix products may continue to be used through their labeled expiration dates.

This regulatory transition is occurring as COVID-19 EUA declarations for medical devices are scheduled to terminate on December 26, 2026, per the U.S. Department of Health and Human Services. Aptitude is also expanding the Metrix menu, with additional products targeting respiratory syncytial virus (RSV), Streptococcus, and sexually transmitted infections in late-stage development or under review. Over the past year, hundreds of clinics have adopted the platform, reflecting rapid uptake in urgent care.

“We're continually developing Metrix to make it better. FDA clearance is an important step, not a stopping point. We continue to push the Metrix platform forward with faster tests, better performance, simpler operations, and a broader menu for our growing customer base,” said JP Wang, co-CEO of Aptitude.

“The opportunity is much larger than replacing existing molecular systems. By removing the economic and operational barriers that have historically limited molecular testing, Metrix can bring molecular diagnostics into healthcare settings where it previously wasn't practical. We believe Metrix can fundamentally expand where and how molecular testing is used,” said Scott Ferguson, co-CEO of Aptitude.

Related Links
Aptitude Medical Systems


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.